ReviewJournal of inflammation research2026
The Therapeutic Effects of Active Components from Food-Medicine Plants on Liver Fibrosis.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis, a chronic progression process of liver disease in which various factors damage the liver, leading to the development of liver inflammation and eventually progressing to liver cirrhosis. Food-medicine plants, which serve dual roles in nutrition and therapy, play a significant role in the management of chronic diseases, particularly within minority communities and developing regions. This review systematically examines the therapeutic potential of bioactive compounds derived from food-medicine plants-such as flavonoids, alkaloids, phenolics, and terpenoids-in mitigating liver fibrosis. These compounds exert their effects through multiple mechanisms, including modulation of key signaling pathways such as TGF-β, PI3K/Akt, ferroptosis, and Wnt/β-catenin. Additionally, they enhance antioxidant enzyme activity, suppress pro-fibrotic mediators, and reduce fibrosis-related biomarkers. Overall, this work underscores the multifaceted mechanisms underlying the anti-fibrotic effects of food-medicine plant products. Nevertheless, further clinical validation is necessary to translate these preclinical insights into effective therapies, thereby providing a foundation for future research and drug development in the management of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.